Lead Product(s) : EG110A
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants IND Clearance for EG 427 Gene Therapy in Neurology
Details : EG110A is a gene therapy for the treatment which works by silencing the type-C neurons, being developed for Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.
Product Name : EG110A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : EG110A
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EG110A
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EG427 Reports New Preclinical Results for EG110A in Neurogenic Detrusor Overactivity
Details : EG110A is based on company's unique non-replicative HSV-1 vector platform. It is being evaluated in preclinical studies for neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Product Name : EG110A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : EG110A
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : IACTA Pharmaceuticals
Deal Size : $100.0 million
Deal Type : Collaboration
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug
Details : Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharm...
Product Name : IC 800
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : IC 800
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : IACTA Pharmaceuticals
Deal Size : $100.0 million
Deal Type : Collaboration
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01
Details : AlgoTherapeutix has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01.
Product Name : ATX01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Amitriptyline Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable